AGP
MGNX icon

Artia Global Partners’s MacroGenics MGNX Stock Holding History

Artia Global Partners’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-64,007
Closed -$942K – 53
2024
Q1 		$942K Buy
+64,007
New +$967K 0.19% 41

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artia Global Partners's MGNX Position: Q2 2024 in Review

Artia Global Partners sold out of MacroGenics (MGNX) in Q2 2024, closing a stake of 64,007 shares — an estimated $942K sold.

Artia Global Partners first reported a position in MGNX in Q1 2024 and held it in 1 quarter. The position peaked at $942K in Q1 2024. 146 funds tracked by Wall St. Rank hold MGNX as of Q2 2024.

  • Artia Global Partners reported no remaining MacroGenics position as of Q2 2024 after selling out during the quarter.
  • Artia Global Partners sold 64,007 MacroGenics shares in Q2 2024, an estimated $942K.
  • Artia Global Partners first reported a position in MacroGenics in Q1 2024 and held it in 1 quarter.
  • Artia Global Partners's MacroGenics position peaked at $942K in Q1 2024.
  • 146 funds tracked by Wall St. Rank held MacroGenics as of Q2 2024.

Based on Artia Global Partners's 13F filing for Q2 2024, filed 14 Aug 2024.